Interleukin 6 (IL6), a pleiotropic cytokine, which is an important player in several cellular processes such as proliferation, immune regulation, inflammation, and invasion, has been shown to be upregulated in various cancer types and also predicts poor clinical outcomes in patients with HNSCC (71–74). This evidence concerns the gene IL6 and cancer.